BACKGROUND: Tuberculin skin testing (TST) and preventive treatment of tuberculosis (TB) are recommended for all persons with human immunodeficiency virus (HIV) infection. We aimed to assess the effect of TST and preventive treatment of TB on the incidence of TB in the era of combination antiretroviral therapy in an area with low rates of TB transmission. METHODS: We calculated the incidence of TB among participants who entered the Swiss HIV Cohort Study after 1995, and we studied the associations of TST results, epidemiological and laboratory markers, preventive TB treatment, and combination antiretroviral therapy with TB incidence. RESULTS: Of 6160 participants, 142 (2.3%) had a history of TB at study entry, and 56 (0.91%) developed TB during a total follow-up period of 25,462 person-years, corresponding to an incidence of 0.22 cases per 100 person-years. TST was performed for 69% of patients; 9.4% of patients tested had positive results (induration > or = 5 mm in diameter). Among patients with positive TST results, TB incidence was 1.6 cases per 100 person-years if preventive treatment was withheld, but none of the 193 patients who received preventive treatment developed TB. Positive TST results (adjusted hazard ratio [HR], 25; 95% confidence interval [CI], 11-57), missing TST results (HR, 12; 95% CI, 4.8-20), origin from sub-Saharan Africa (HR, 5.8; 95% CI, 2.7-12.5), low CD4+ cell counts, and high plasma HIV RNA levels were associated with an increased risk of TB, whereas the risk was reduced among persons receiving combination antiretroviral therapy (HR, 0.44; 95% CI, 0.2-0.8). CONCLUSION: Screening for latent TB using TST and administering preventive treatment for patients with positive TST results is an efficacious strategy to reduce TB incidence in areas with low rates of TB transmission. Combination antiretroviral therapy reduces the incidence of TB.
BACKGROUND: Tuberculin skin testing (TST) and preventive treatment of tuberculosis (TB) are recommended for all persons with human immunodeficiency virus (HIV) infection. We aimed to assess the effect of TST and preventive treatment of TB on the incidence of TB in the era of combination antiretroviral therapy in an area with low rates of TB transmission. METHODS: We calculated the incidence of TB among participants who entered the Swiss HIV Cohort Study after 1995, and we studied the associations of TST results, epidemiological and laboratory markers, preventive TB treatment, and combination antiretroviral therapy with TB incidence. RESULTS: Of 6160 participants, 142 (2.3%) had a history of TB at study entry, and 56 (0.91%) developed TB during a total follow-up period of 25,462 person-years, corresponding to an incidence of 0.22 cases per 100 person-years. TST was performed for 69% of patients; 9.4% of patients tested had positive results (induration > or = 5 mm in diameter). Among patients with positive TST results, TB incidence was 1.6 cases per 100 person-years if preventive treatment was withheld, but none of the 193 patients who received preventive treatment developed TB. Positive TST results (adjusted hazard ratio [HR], 25; 95% confidence interval [CI], 11-57), missing TST results (HR, 12; 95% CI, 4.8-20), origin from sub-Saharan Africa (HR, 5.8; 95% CI, 2.7-12.5), low CD4+ cell counts, and high plasma HIV RNA levels were associated with an increased risk of TB, whereas the risk was reduced among persons receiving combination antiretroviral therapy (HR, 0.44; 95% CI, 0.2-0.8). CONCLUSION: Screening for latent TB using TST and administering preventive treatment for patients with positive TST results is an efficacious strategy to reduce TB incidence in areas with low rates of TB transmission. Combination antiretroviral therapy reduces the incidence of TB.
Authors: Lukas Fenner; Sebastien Gagneux; Peter Helbling; Manuel Battegay; Hans L Rieder; Gaby E Pfyffer; Marcel Zwahlen; Hansjakob Furrer; Hans H Siegrist; Jan Fehr; Marisa Dolina; Alexandra Calmy; David Stucki; Katia Jaton; Jean-Paul Janssens; Jesica Mazza Stalder; Thomas Bodmer; Beatrice Ninet; Erik C Böttger; Matthias Egger Journal: J Clin Microbiol Date: 2011-11-23 Impact factor: 5.948
Authors: Asha Anandaiah; Keertan Dheda; Joseph Keane; Henry Koziel; David A J Moore; Naimish R Patel Journal: Am J Respir Crit Care Med Date: 2010-12-22 Impact factor: 21.405
Authors: Julia del Amo; Santiago Moreno; Heiner C Bucher; Hansjakob Furrer; Roger Logan; Jonathan Sterne; Santiago Pérez-Hoyos; Inma Jarrín; Andrew Phillips; Sara Lodi; Ard van Sighem; Wolf de Wolf; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; José M Miró; Elena Ferrer; Laurence Meyer; Rémonie Seng; Giota Toulomi; Panagiotis Gargalianos; Dominique Costagliola; Sophie Abgrall; Miguel A Hernán Journal: Clin Infect Dis Date: 2012-03-28 Impact factor: 9.079
Authors: Timothy R Sterling; Bryan Lau; Jinbing Zhang; Aimee Freeman; Ronald J Bosch; John T Brooks; Steven G Deeks; Audrey French; Stephen Gange; Kelly A Gebo; M John Gill; Michael A Horberg; Lisa P Jacobson; Gregory D Kirk; Mari M Kitahata; Marina B Klein; Jeffrey N Martin; Benigno Rodriguez; Michael J Silverberg; James H Willig; Joseph J Eron; James J Goedert; Robert S Hogg; Amy C Justice; Rosemary G McKaig; Sonia Napravnik; Jennifer Thorne; Richard D Moore Journal: J Infect Dis Date: 2011-09-15 Impact factor: 5.226
Authors: Jonathan E Golub; Jacquie Astemborski; Mohammed Ahmed; Wendy Cronin; Shruti H Mehta; Gregory D Kirk; David Vlahov; Richard E Chaisson Journal: J Acquir Immune Defic Syndr Date: 2008-12-15 Impact factor: 3.731
Authors: A C Pettit; G Barkanic; S Stinnette; P Rebeiro; R Blackwell; S P Raffanti; B E Shepherd; T R Sterling Journal: Int J Tuberc Lung Dis Date: 2009-03 Impact factor: 2.373
Authors: Barbara Hasse; A Sarah Walker; Jan Fehr; Hansjakob Furrer; Matthias Hoffmann; Manuel Battegay; Alexandra Calmy; Jacques Fellay; Caroline Di Benedetto; Rainer Weber; Bruno Ledergerber Journal: Antimicrob Agents Chemother Date: 2014-02-10 Impact factor: 5.191